These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15865061)

  • 1. Docking studies on NSAID/COX-2 isozyme complexes using contact statistics analysis.
    Ermondi G; Caron G; Lawrence R; Longo D
    J Comput Aided Mol Des; 2004 Nov; 18(11):683-96. PubMed ID: 15865061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for the observed COX-2/COX-1 selectivity of celecoxib from Monte Carlo simulations.
    Price ML; Jorgensen WL
    Bioorg Med Chem Lett; 2001 Jun; 11(12):1541-4. PubMed ID: 11412976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity.
    Yamakawa N; Suzuki K; Yamashita Y; Katsu T; Hanaya K; Shoji M; Sugai T; Mizushima T
    Bioorg Med Chem; 2014 Apr; 22(8):2529-34. PubMed ID: 24650702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of the dynamic mechanism of ligand binding to cyclooxygenase.
    Llorens O; Perez JJ; Palomer A; Mauleon D
    Bioorg Med Chem Lett; 1999 Oct; 9(19):2779-84. PubMed ID: 10522690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere.
    Habeeb AG; Praveen Rao PN; Knaus EE
    J Med Chem; 2001 Aug; 44(18):3039-42. PubMed ID: 11520213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modelling of the differential interaction between several non-steroidal anti-inflammatory drugs and human prostaglandin endoperoxide H synthase-2 (h-PGHS-2).
    Pouplana R; Lozano JJ; Ruiz J
    J Mol Graph Model; 2002 Jan; 20(4):329-43. PubMed ID: 11858641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2.
    Luong C; Miller A; Barnett J; Chow J; Ramesha C; Browner MF
    Nat Struct Biol; 1996 Nov; 3(11):927-33. PubMed ID: 8901870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential binding mode of diverse cyclooxygenase inhibitors.
    Llorens O; Perez JJ; Palomer A; Mauleon D
    J Mol Graph Model; 2002 Mar; 20(5):359-71. PubMed ID: 11885959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.
    Palomer A; Cabré F; Pascual J; Campos J; Trujillo MA; Entrena A; Gallo MA; García L; Mauleón D; Espinosa A
    J Med Chem; 2002 Mar; 45(7):1402-11. PubMed ID: 11906281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.
    Everts B; Währborg P; Hedner T
    Clin Rheumatol; 2000; 19(5):331-43. PubMed ID: 11055820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2).
    García-Nieto R; Pérez C; Gago F
    J Comput Aided Mol Des; 2000 Feb; 14(2):147-60. PubMed ID: 10721503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of COX-2 selectivity into flurbiprofen.
    Bayly CI; Black WC; Léger S; Ouimet N; Ouellet M; Percival MD
    Bioorg Med Chem Lett; 1999 Feb; 9(3):307-12. PubMed ID: 10091674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
    Weber A; Casini A; Heine A; Kuhn D; Supuran CT; Scozzafava A; Klebe G
    J Med Chem; 2004 Jan; 47(3):550-7. PubMed ID: 14736236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theoretical studies on the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site?
    Soliva R; Almansa C; Kalko SG; Luque FJ; Orozco M
    J Med Chem; 2003 Apr; 46(8):1372-82. PubMed ID: 12672237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for selective inhibition of COX-2 by nimesulide.
    Fabiola GF; Pattabhi V; Nagarajan K
    Bioorg Med Chem; 1998 Dec; 6(12):2337-44. PubMed ID: 9925294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 inhibitors.
    Hawkey CJ
    Lancet; 1999 Jan; 353(9149):307-14. PubMed ID: 9929039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations.
    Selinsky BS; Gupta K; Sharkey CT; Loll PJ
    Biochemistry; 2001 May; 40(17):5172-80. PubMed ID: 11318639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 19. COX-2 selectivity and inflammatory processes.
    van Ryn J; Trummlitz G; Pairet M
    Curr Med Chem; 2000 Nov; 7(11):1145-61. PubMed ID: 11032964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structure of mammalian cyclooxygenases.
    Garavito RM; Mulichak AM
    Annu Rev Biophys Biomol Struct; 2003; 32():183-206. PubMed ID: 12574066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.